Hypercholesterolemia is a recognized risk factor for development of atherosclerosis in both native coronary arteries and bypass grafts. Lipid-lowering therapy with statins is effective. Few data are available for studies on bypass grafts. The influence of hypercholesterolemia on development of bypass graft disease was studied.
Clinical and angiographic follow up 1 yr after CABG of patients with a preoperative cholesterol > 6.2 mmol/l, with a preoperative lipid control (group 2) or controls (group 1) and patients with cholesterol < 4.7 mmol/1 (group 3) were studied. Patient demographics, angiography and operation data were the same in all the groups.
Group 1 patients had significantly higher incidence of graft lesions, requiring more interventions than Group 2. Sequential vein bypass grafts showed superior features compared to single vein grafts.
Preoperative lipid control with statins is strongly recommended, since uncontrolled hypercholesterolemia has a direct impact on the outcome of CABG procedure. It significantly reduces the development of vein graft obstructive disease.
CampeauL.EnjalbertM.LespéranceJ.VaislicC.GrondinC.M.BourassaM.G., Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years and 10 to 12 years after surgery. Circulation, 1983, 68(Suppl. II), 1–7.
2.
BourassaM.G.FisherL.D.CampeauL.GillespieM.D.McConneyM.LespéranceJ., Long-term fate of bypass grafts. The Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences. Circulation, 1985, 72, V–71.
3.
ChristensonJ.T.SchmuzigerM., Sequential venous bypass grafts: results 10 years later. Annals of Thoracic Surgery, 1997, 63, 371–376.
ReichleF.A.StewartG.J.EssaN., A transmission and scanning electron microscopic study of luminal surfaces in Dacron and autogenous vein bypasses in man and dog. Surgery, 1973, 74(6), 945–960.
6.
BulkleyB.H.HutchkinsG.M., Accelerated ‘atherosclerosis’. A morphologic study of 97 saphenous vein coronary artery bypass grafts. Circulation, 1977, 56(3), 163–169.
KramerJ.R.MatsudaY.MulliganJ.C.AronowM.ProudfitW.L., Progression of coronary atherosclerosis. Circulation, 1981, 63, 519–526.
9.
KirklinJ.W.Barrett-BoyesB.G., eds. Stenotic coronary artery disease. In Cardiac Surgery, Vol. 1, 2nd edn.Churchill Livingstone, New York, 1994, p. 290.
10.
FerrieresJ.TaraszkiewicsD.RuidavetsJ.B., Prevalence and management of major risk factors in 500 men with stable coronary disease. Annals of Cardiology and Angiology, 1998, 47(8), 543–548.
11.
WrightJ.StrangJ.R., Reducing the risk after coronary artery bypass surgery: documentation of risk factors and communication between hospital and general practice. Public Health (England), 1997, 111(3), 157–160.
12.
WatersD.HigginsonL.GladstoneP., Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation, 1994, 89, 959–968.
13.
BrownG.AlbersJ.J.FisherL.D., Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New England Journal of Medicine, 1990, 323(19), 1289–1298.
14.
MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study. Lancet, 1994, 344, 633–638 [erratum, Lancet, 1994, 344, 762].
15.
JukemaJ.W.BruschkeA.V.G.Van BovenA.J., Effects of lipid-lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation, 1995, 91, 2528–2540.
16.
BlakenhornD.H.NessimS.A.JohnsonR.L.SanmarcoM.E.AzenS.P.Cashin-HemphillL., Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA, 1987, 257(23), 3233–3240.
17.
The post Coronary Artery bypass Graft trial Investigators. The Effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. New England Journal of Medicine, 1997, 326(3), 153–162.
18.
ChristensonJ.T., Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. European Journal of Cardiothoracic Surgery, 1999, 15, 394–400.
19.
SolymossB.C.NadeauP.MilletteD.CampeauL., Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation, 1988, 78(3Pt2), 140–143.
20.
CrouseJ.R.IIIFrolichJ.OseL.MercuriM.TobertJ.A., Effects of high doses of simvastatin and atorvastin on high-density lipoprotein cholesterol and apolipoprotein A-I. American Journal of Cardiology, 1999, 83, 1476–1477.
21.
RosensonR.S.TangneyC.C., Anti-artherothrombotic properties of statin. Implications of cardiovascular event reduction. JAMA, 1998, 279, 1643–1650.
22.
PedersenT.R.KjekshusJ.BergK., Scandinavian Simvastatin Survival Study Investigators. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383–1389.
23.
ShepardJ.CobbeS.M.FordI., West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine, 1995, 333, 1301–1306.
24.
JönssonB.JohannessonK.KjekhusJ.OlssonA.G.PedersenT.R.WedelH., Scandinavian simvastatin survival study Group. Cost effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal, 1996, 17, 1001–1007.
25.
AzenS.P.MackW.J.Cashin-HemphillL., Progression of coronary artery disease predicts coronary events. Long-term follow-up from the cholesterol lowering atherosclerosis study. Circulation, 1996, 93(5), 2367–2374.
26.
MeiserW.K.NagelT.J.Von ScheidtW.SteinbeckG.SeidelD.ReichartB., Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four year randomized trial. Circulation, 1997, 96(5), 1398–1402.
27.
JahangiriM.KovacsI.B.RidlerC.D.ReesG.M.GorogP., Coronary artery surgery with different forms of atherogenic lipoprotein modifications. Annals of Thoracic Surgery, 1999, 67, 652–656.
28.
BjorkerudB.BjorkerudS., Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages and fibroblasts. Arteriosclerosis Thrombosis and Vascular Biology, 1996, 16, 416–424.
29.
LoopF.D.LytleB.W.CosgroveD.M., Influence of the internal mammary artery graft on 10 years survival and cardiac events. New England Journal of Medicine, 1986, 314(1), 1–6.
30.
SmithS.H.GeerJ.C., Morphology of saphenous vein coronary artery bypass grafts 7–116 months postoperatively, and by 10 years all grafts have atherosclerosis. Archives of Pathology Laboratory Medicine, 1983, 107(1), 13–18.
31.
SacksF.M.PfefferM.A.MoyeL.A., The effect of pravastatin on coronary events after myocardial infraction in patients with average cholesterol levels. New England Journal of Medicine, 1996, 335(14), 1001–1009.
